Beam Therapeutics (BEAM) Short term Debt (2019 - 2025)
Historic Short term Debt for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $6.5 million.
- Beam Therapeutics' Short term Debt fell 2261.9% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year decrease of 2261.9%. This contributed to the annual value of $8.4 million for FY2024, which is 2222.22% down from last year.
- Latest data reveals that Beam Therapeutics reported Short term Debt of $6.5 million as of Q3 2025, which was down 2261.9% from $3.9 million recorded in Q2 2025.
- Beam Therapeutics' Short term Debt's 5-year high stood at $85.4 million during Q2 2021, with a 5-year trough of $3.9 million in Q2 2025.
- Its 5-year average for Short term Debt is $22.9 million, with a median of $13.6 million in 2023.
- In the last 5 years, Beam Therapeutics' Short term Debt soared by 59619.05% in 2021 and then crashed by 8079.63% in 2022.
- Quarter analysis of 5 years shows Beam Therapeutics' Short term Debt stood at $42.2 million in 2021, then plummeted by 56.64% to $18.3 million in 2022, then crashed by 40.98% to $10.8 million in 2023, then decreased by 22.22% to $8.4 million in 2024, then dropped by 22.62% to $6.5 million in 2025.
- Its Short term Debt was $6.5 million in Q3 2025, compared to $3.9 million in Q2 2025 and $5.2 million in Q1 2025.